Live Breaking News & Updates on Vac media

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Belgium , Netherlands , Germany , Switzerland , Boston , Massachusetts , United-states , Patrick-perez , Alexander-zehnder , Dennis-riedl , Sarah-fakih , Thaminda-ramanayake

EQS-News: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer | Company Announcement

Investegate announcements from EQS-News: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Netherlands , Belgium , Switzerland , United-states , Germany , Thaminda-ramanayake , Sarah-fakih , Alexander-zehnder , Patrick-perez , Corporate-communications , University-of-rochester-simon-school-business , University-of-rochester-strong-medical-center

EQS-News: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

EQS-News: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

Switzerland , Netherlands , Australia , Germany , Belgium , United-states , Sarah-fakih , Myriam-mendila , Vaccine-development-program-in-collaboration , Corporate-communications , Strong-validation-of-proprietary-technology-platform , Curevac-announces-positive-phase

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Switzerland , United-states , Boston , Massachusetts , Belgium , Netherlands , Germany , Australia , Sarah-fakih , Myriam-mendila , Corporate-communications , Exchange-commission

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collabo

Issuer: CureVac / Key word(s): Study results05.01.2024 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platf.

Belgium , Germany , Netherlands , Switzerland , United-states , Australia , Myriam-mendila , Sarah-fakih , Vaccine-development-program-in-collaboration , Curevac-corporate-services-gmb , Distribution-services , Strong-validation-of-proprietary-technology-platform